Medical innovator Proteomics International Laboratories is charging into selling mode after locking away $4.5 million from institutional and sophisticated investors to fast-track the roll-out of its novel Promarker diagnostic tests across Australia and the United States.
The Perth-based biotech is known for its pioneering work in predictive diagnostics through the large-scale study of proteins.
